Upon recognizing the ongoing nation-wide drug shortages that Canadians continue to face, we launched our Drug Shortage Division in 2022 in order to become a part of the solution. Providing Canadians with access to global medications in times of critical shortage is the goal, and our team works diligently to ensure these goals are met. By continuously analyzing market updates and trends, our team is on the lookout for any opportunity to fill the needs and demands of Canadians and ensure they are receiving the best treatments possible.
With over 140 manufacturers globally, we’ve built a strong network of sourcing agents who help us meet the necessary demands within the Canadian market. By regularly communicating with our network – some of which include: Europe, India, China, Australia, New Zealand, and South Africa – we work to source drugs that have been identified as short supply by patients, customers, industry, and Health Canada.
Our Drug Shortage Division’s first milestone came when we successfully imported Amoxicillin suspension for children amongst a severe ongoing national shortage. With countless drug shortages remaining, there is no time to stop – so we aggressively continue to pursue other shortages within the Canadian market.
The Juno Canada Drug Shortage Division is currently working on a number of medicines to bring to Canada in the following channels:
- Pharmacy and hospital focused antibiotics
- Emergency room and critical care medicines
- Operating theater medicines used in anesthesia and respiratory care
